Fulcrum Therapeutics to Present at Investor Meetings in September 2025

Fulcrum Therapeutics will present at two healthcare investment conferences in September 2025, the Cantor Fitzgerald 2025 Annual Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. CEO Alex Sapir, CFO Alan Musso, and SVP Iain Fraser will represent the company and engage in fireside chats. Investors can schedule one-on-one meetings with the company's management or access webcast replays on Fulcrum Therapeutics' Investor Relations Events and Presentations page. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases, will present at two major healthcare investment conferences in September 2025. The company will participate in the Cantor Fitzgerald 2025 Annual Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. CEO Alex Sapir, CFO Alan Musso, and Senior Vice President of Early Development Iain Fraser will represent the company and engage in fireside chats.

Cantor Fitzgerald 2025 Annual Global Healthcare Conference
The conference will take place on September 4, 2025, in New York, NY. The fireside chat, titled "Fulcrum Therapeutics: Innovations in Rare Disease Treatment," will feature CEO Alex Sapir, CFO Alan Musso, and SVP Iain Fraser. The event will be streamed live and will be available for replay on Fulcrum Therapeutics' Investor Relations Events and Presentations page for at least 30 days following the presentation [1].

H.C. Wainwright 27th Annual Global Investment Conference
The conference will be held on September 9, 2025, in New York, NY. Fulcrum Therapeutics will present a company overview at this event. The presentation will be led by CEO Alex Sapir, CFO Alan Musso, and SVP Iain Fraser. The webcast will also be available for replay on the company's Investor Relations Events and Presentations page [2].

About Fulcrum Therapeutics
Fulcrum Therapeutics is dedicated to developing small molecules to improve the lives of patients with rare diseases. Its lead clinical program, pociredir, is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED), designed to increase the expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). The company uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression [1][2].

About Pociredir
Pociredir has demonstrated proof-of-concept in SCD, achieving absolute levels of HbF increases associated with potential overall patient benefit. The drug has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of SCD. Initial data showed that pociredir was generally well-tolerated in people with SCD with up to three months of exposure, with no serious treatment-related adverse events reported [1][2].

Contact Information
Investors interested in scheduling one-on-one meetings with Fulcrum Therapeutics' management can contact their respective representatives at the sponsoring institutions. For more information, visit Fulcrum Therapeutics' website at www.fulcrumtx.com or follow them on Twitter/X (@FulcrumTx) and LinkedIn.

References
[1] https://ir.fulcrumtx.com/news-releases/news-release-details/fulcrum-therapeutics-present-upcoming-investor-meetings
[2] https://www.globenewswire.com/news-release/2025/08/26/3139186/0/en/Fulcrum-Therapeutics-to-Present-at-Upcoming-Investor-Meetings.html